EFG International AG Takes $4.86 Million Position in Halozyme Therapeutics, Inc. $HALO

EFG International AG bought a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 62,029 shares of the biopharmaceutical company’s stock, valued at approximately $4,855,000. EFG International AG owned approximately 0.05% of Halozyme Therapeutics at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in HALO. Canada Pension Plan Investment Board purchased a new position in Halozyme Therapeutics during the second quarter valued at approximately $10,379,000. Legal & General Group Plc purchased a new stake in shares of Halozyme Therapeutics in the second quarter worth $25,288,000. The Manufacturers Life Insurance Company bought a new stake in shares of Halozyme Therapeutics during the 2nd quarter valued at $13,624,000. Kelly Lawrence W & Associates Inc. CA bought a new stake in shares of Halozyme Therapeutics during the 2nd quarter valued at $117,000. Finally, Cetera Trust Company N.A purchased a new position in shares of Halozyme Therapeutics during the 2nd quarter valued at $489,000. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO opened at $109.32 on Wednesday. The firm has a market cap of $12.41 billion, a price-to-earnings ratio of 32.63, a P/E/G ratio of 0.44 and a beta of 0.85. The firm has a fifty day moving average price of $84.73 and a 200 day moving average price of $74.19. Halozyme Therapeutics, Inc. has a fifty-two week low of $61.22 and a fifty-two week high of $109.55. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.79 by $0.49. The company had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. Halozyme Therapeutics’s revenue for the quarter was up 47.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, sell-side analysts expect that Halozyme Therapeutics, Inc. will post 7.77 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on HALO shares. Weiss Ratings downgraded shares of Halozyme Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, August 14th. Wells Fargo & Company raised their price target on Halozyme Therapeutics from $75.00 to $95.00 and gave the company an “equal weight” rating in a report on Friday, August 7th. Wall Street Zen upgraded Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Leerink Partners raised Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $83.00 to $110.00 in a research note on Friday, August 7th. Finally, HC Wainwright increased their target price on Halozyme Therapeutics from $95.00 to $115.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Nine equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $91.20.

Insider Activity

In other news, Director Bernadette Connaughton sold 1,626 shares of Halozyme Therapeutics stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $102.80, for a total value of $167,152.80. Following the sale, the director directly owned 40,418 shares of the company’s stock, valued at approximately $4,154,970.40. The trade was a 3.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the business’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $75.00, for a total value of $547,800.00. Following the completion of the sale, the director owned 14,462 shares in the company, valued at $1,084,650. This represents a 33.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 64,103 shares of company stock worth $5,226,496 over the last 90 days. Corporate insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.